Cholesterol-lowering drug shows promise in clinical trial
The drug could prove effective in populations of patients intolerant to statins.
A new cholesterol-lowering drug has shown promise in a phase 2a clinical trial, and plans to conduct the next stage of the experiment are already in motion.
Biopharmaceutical company Esperion Therapeutics tested its first-in-class oral low-density lipoprotein cholesterol-lowering medicine in a cohort of patients with hypercholesterolemia.
Approximately 2.6 million deaths per year are attributable to elevated cholesterol in the blood, according to the World Health Organization (WHO), showing that the market for drugs is large.
One of the main benefits of the ETC-1002 is that it has demonstrated the ability to reduce cholesterol levels in patients who have an intolerance to statins, the drugs typically prescribed.
It could therefore act as a safe alternative to a large group of patients, with trial results indicating cholesterol levels could be lowered by around 32 per cent.
Dr Paul D Thompson, of Hartford Hospital and the University of Connecticut said: "A well-tolerated medication that significantly lowers LDL-C could benefit this underserved patient population."
Related News
-
News CPHI Frankfurt 2022: Innovator Interview – DSM Biomedical
At CPHI Frankfurt we spoke to Anne-Cecile Bayne, Global Science & Innovation Lead Pharma and Medical Nutrition, and Marc Hendriks, Vice President Strategy & Business Development, on their expertise in nitrosamines and business strategy at DSM Biomedica... -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled. -
News Magic mushrooms could be used to treat mental health conditions
A compound found in magic mushrooms, psilocybin, could be used to treat mental health conditions and help patients suffering with severe depression, as shown by the results of the largest study of its kind to date. -
News UK-based partnership to launch DETERMINE study into rare cancer research
UK-based CRO Quanticate is set to partner with Cancer Research UK for the launch of the DETERMINE study focused on testing a range of existing and approved drugs and therapies on rare cancers. -
News FDA approves Thermo Fisher blood tests for wheat and sesame allergies
Both tests have been approved by the US regulator for in vitro diagnostic use -
News QIAGEN launches world’s first syndromic test for monkeypox
The test can distinguish between monkeypox and other diseases that cause similar symptoms. -
News Monkeypox Update: Vaccine shortage, sewage surveillance and global testing
As concern over the monkeypox outbreak continues to rise, we take a look at major developments from the first week of August. -
News CPHI Podcast Series: The importance of novel excipients for innovative drug development
The latest episode in the CPHI Podcast Series dives into the world of novel excipients and explores their importance for innovative drug development.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance